Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × OTHER × tofacitinib × Clear all

Phase

Phase 2 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 8 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cisplatin 251 Radiotherapy 208 Fluorouracil 182 Cyclophosphamide 171 Capecitabine 168 Oxaliplatin 149 Docetaxel 148 Gemcitabine 139 Paclitaxel 133 Carboplatin 133 Dexamethasone 111 Leucovorin 110 Drug Therapy 104 Doxorubicin 103 Etoposide 87 Bevacizumab 79 Vincristine 77 Cytarabine 77 Irinotecan 73 Rituximab 69 Epirubicin 64 Prednisone 60 Methotrexate 56 Radiosurgery 53 Radiation 53 Surgical Procedures, Operative 51 Radiotherapy, Intensity-Modulated 50 Lenalidomide 49 Neoadjuvant Therapy 48 Letrozole 46

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05326464 2025-12-15

Tofacitinib in Recurrent GBM Patients

University of Texas Southwestern Medical Center

Phase 3 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡